Multi-omics analysis revealed distinct drug responses and immune profiles in acute myeloid leukemia, indicating potential for personalized treatment strategies.
Key Points
Venetoclax response was significantly linked to specific multi-omics factors in acute myeloid leukemia patients.
Analysis identified four immune microenvironment subtypes with clear differences in drug sensitivity patterns.
Integrative multi-omics data revealed associations between gene mutations and drug resistance in acute myeloid leukemia.
Findings support targeted therapies based on patient-specific tumor characteristics to improve treatment outcomes.